Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 7, 2019-- NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest , effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and
5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 4, 2019-- Patrick Soon-Shiong , MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage,
Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jun.
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions CULVER CITY, Calif. --(BUSINESS WIRE)--May 31, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage,
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Brink Biologics, Inc. , a NantKwest, Inc.
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019 CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has
